LSA
TSHA icon

Leonteq Securities AG’s Taysha Gene Therapies TSHA Stock Holding History

Leonteq Securities AG’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,999
Closed -$154K – 1487
2025
Q4 		$154K Hold
27,999
– – ﹤0.01% 718
2025
Q3 		$91.6K Hold
27,999
– – ﹤0.01% 768
2025
Q2 		$64.7K Sell
27,999
-52,000
-65% -$113K ﹤0.01% 802
2025
Q1 		$111K Hold
79,999
– – 0.01% 677
2024
Q4 		$138K Sell
79,999
-1
-0% -$2 0.01% 617
2024
Q3 		$161K Buy
80,000
+27,000
+51% +$59.2K 0.01% 534
2024
Q2 		$119K Buy
53,000
+25,000
+89% +$72.8K 0.01% 590
2024
Q1 		$80.4K Buy
28,000
+20,000
+250% +$41.7K 0.01% 680
2023
Q4 		$14.2K Buy
8,000
+3,000
+60% +$5.98K ﹤0.01% 973
2023
Q3 		$15.8K Buy
+5,000
New +$9.34K ﹤0.01% 972

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Leonteq Securities AG's TSHA Position: Q1 2026 in Review

Leonteq Securities AG sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 27,999 shares — an estimated $154K sold.

Leonteq Securities AG first reported a position in TSHA in Q3 2023 and held it in 10 quarters. The position peaked at $161K in Q3 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Leonteq Securities AG reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Leonteq Securities AG sold 27,999 Taysha Gene Therapies shares in Q1 2026, an estimated $154K.
  • Leonteq Securities AG first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 10 quarters.
  • Leonteq Securities AG's Taysha Gene Therapies position peaked at $161K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Leonteq Securities AG's 13F filing for Q1 2026, filed 27 Apr 2026.